Drugs / GFH375
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07259590 | Oct 2025 → Jul 2027 expected | colorectal cancer, pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06500676 | Jul 2024 → Jul 2028 expected | cancer | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07554859 | May 2026 → Apr 2027 expected | non-small cell lung carcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07026916 | Aug 2025 → Aug 2027 | malignant pancreatic neoplasm | Genfleet Therapeutics (Shanghai) Inc. | Withdrawn | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07668752 | Jul 2026 → Jun 2030 expected | non-small cell lung carcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07262567 | Dec 2025 → Jun 2027 expected | malignant pancreatic neoplasm | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFH375 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06500676 ↗ |
| Action | Inhibit | “GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation.” NCT07668752 ↗ |
| Modality | Small molecule | “GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation.” NCT07668752 ↗ |
| Route | Oral | “orally” NCT06500676 ↗ |
| Target | KRAS | “targeting the KRAS G12D mutation” NCT07668752 ↗ |